Advanced SearchSearch Tips
Molecular Docking Study of Novel Anti-Hepatitis B Virus Agents Isolated from Talaromyces Species
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
  • Journal title : Journal of the Chosun Natural Science
  • Volume 9, Issue 1,  2016, pp.23-27
  • Publisher : The Research Institute of Chosun Natural Science
  • DOI : 10.13160/ricns.2016.9.1.23
 Title & Authors
Molecular Docking Study of Novel Anti-Hepatitis B Virus Agents Isolated from Talaromyces Species
Babu, Sathya;
  PDF(new window)
Hepatitis B virus is the leading source of liver disorders and is a global health problem and needs advancements in its treatment against increasing problems. Recently five vanitaracin derivatives were isolated from the fungus Talaromyces species which have anti-Hepatitis B virus activity. Hence, in the present study, molecular docking was carried out with five vanitaracin derivatives isolated from Talaromyces species and three known inhibitors.The objective of this work is to study the interaction of newly isolated compounds and compare its interaction with known inhibitors. The docking results revealed that vanitaracin derivatives have good interactions and has better docking score with the Hepatitis B virus and suggest SER2, SER4 and ASP30 are important residues involved in interaction with the inhibitors. These result authenticates vanitaracin derivatives contributes to inhibitory activity of Hepatitis B virus to treat liver disorders.
Hepatitis B Virus;Talaromyces Species;Molecular Docking;
 Cited by
T. J. Liang, "Hepatitis B: the virus and disease", Hepatology, Vol. 49, pp. S13-S21, 2009. crossref(new window)

N. Gitilin, "HepatitisB: diagnosis, prevention and treatment", Clin. Chem., Vol. 43, pp. 1500-1506, 1997.

M. Rizzetto and A. Ciancio, "Chronic HBV-related liver disease", Mol. Aspects Med., Vol. 29, pp. 72-84, 2008. crossref(new window)

N. Liu, F. Zhao, H. Jia, D. Rai, P. Zhan, X. Jiang, and X. Liu, "Non-nucleoside anti-HBV agents: advances in structural optimization and mechanism of action investigations", Med. Chem. Commun., Vol. 6, pp. 521-535, 2015. crossref(new window)

D. Lavanchy, "Hepatitis B virus epidemiology, disease burden, treatment, current and emerging prevention and control measures", J. Viral Hepatitis, Vol.11, pp. 97-107, 2004. crossref(new window)

K. H. Kim, N. D. Kim, and B. L. Seong, "Discovery and development of anti-HBV agents and their resistance", Molecules, Vol. 15, pp. 5878-5908, 2010. crossref(new window)

Y. Li, L. Fu, H. Yeo, J. L. Zhu, C. K. Chou, Y. H. Kou, S. F. Yeh, E. Gullen, D. Austin, and Y. C. Cheng, "Inhibition of hepatitis B virus gene expression and replication by helioxanthin and its derivative", Antiviral Chemistry & Chemotherapy, Vol. 16, pp. 193-201, 2005. crossref(new window)

E. De Clercq, G. Ferir, S. Kaptein, and J. Neyts, "Antiviral treatment of chronic hepatitis B virus (HBV) infections", Viruses, Vol. 2, pp.1279-1305, 2010. crossref(new window)

H. Kwon and A. S. Lok, "Hepatitis B therapy", Nat. Rev. Gastro. Hepat., Vol. 8, pp. 275-284, 2011. crossref(new window)

T. M. Block, R. Gish, H. Guo, A. Mehta, A. Cuconati, W. T. London, and J. Guo, "Chronic hepatitis B: what should be the goal for new therapies?", Antivir. Res., Vol. 98, pp. 27-34, 2013. crossref(new window)

B. Liu, X. Wen, C. Huang, and Y. Wei, "Unraveling the complexity of hepatitis B virus: From molecular understanding to therapeutic strategy in 50 years", Int. J. Biochem. Cell B., Vol. 45, pp. 1987-1996, 2013. crossref(new window)

K. Sato and M. Mori, "Current and novel therapies for Hepatitis B virus infection", Mini-Rev. Med. Chem., Vol. 10, pp. 20-31, 2010. crossref(new window)

F. Zoulim and S. Locarnini, "Management of treatment failure in chronic hepatitis B", J. Hepatol., Vol. 56, pp. S112-S122, 2012.

A. S. Lok, "Combination Nucleos(t)ide Analogue as Initial Treatment for Chronic Hepatitis B: Have We Put This to Rest?", Hepatology, Vol. 58, pp. 483-485, 2013. crossref(new window)

P. R. Daga, J. Duan, and R. J. Doerksen, "Computational model of hepatitis B virus DNA polymerase: Molecular dynamics and docking to understand resistant mutations", Protein Sci., Vol. 19, pp. 796-807, 2010. crossref(new window)

S. Locarnini, and W. S. Mason, "Cellular and virological mechanisms of HBV drug resistance", J. Hepatol., Vol. 44, pp. 422-431, 2006. crossref(new window)

F. Perveen, R. Qureshi, F. L. Ansari, S. Kalsoom, and S. Ahmed, "Investigations of drug-DNA interactions using molecular docking, cyclic voltammetry and UV-Vis spectroscopy", J. Mol. Struct., Vol. 1004, pp. 67-73, 2011. crossref(new window)

B. Sathya, "Molecular docking study of naturally-derived neuraminidase inhibitors isolated from phellinus baumii", J. Chosun Natural Sci. Vol. 8, pp. 209-213, 2015. crossref(new window)

M. Thirumurthy, "A docking study of newly found natural neuraminidase inhibitor: Erystagallin A", J. Chosun Natural Sci., Vol. 4, pp. 273-277, 2011.

C. G. Gadhe, "Comparative modeling of human P-gp NBD2 and docking and binding mode analysis of 8-geranyl chrysin as a P-gp modulator", J. Chosun Natural Sci., Vol. 5, pp. 18-21, 2012. crossref(new window)

SYBYL Software, Tripos Associates Inc, St. Louis, USA, 2006.

The PyMOL Molecular Graphics System, Version 1.7.4 Schrodinger, LLC.

H. Matsunaga, S. Kamisuki, M. Kaneko, Y. Yamaguchi, T. Takeuchi, K. Watashi, and F. Sugawara, "Isolation and structure of vanitaracin A, a novel anti-hepatitis B viruscompound from Talaromyces sp.", Bioorg. Med. Chem. Lett., Vol. 25, pp. 4325-4328, 2015. crossref(new window)

A. N. Jain, "Scoring functions for protein-ligand docking", Curr. Protein Pept. sc., Vol. 7, pp. 407-420, 2006. crossref(new window)

A. N. Jain, "Scoring non-covalent protein-ligand interactions: a continuous differentiable function tuned to compute binding affinities", J. Comput. Aid. Mol. Des., Vol. 10, pp. 427-440, 1996. crossref(new window)